TransThera Gets US FDA Fast Track Designation for Prostate Cancer Drug; Shares Up 3%

MT Newswires Live

2025/06/24

TransThera Sciences (HKG:2617) said the US Food and Drug Administration has granted fast-track designation for tinengotinib to treat metastatic castration-resistant prostate cancer (mCRPC), according to a Tuesday Hong Kong bourse filing.

In a phase 1/2 study, the drug showed a 46% objective response rate and 85% disease control rate among 13 mCRPC patients with measurable disease, the filing said.

TransThera said the latest designation reflects consistent clinical execution and supports further development of the drug for advanced prostate cancer.

Shares of the clinical-stage biopharmaceutical firm rose about 3% in recent trade.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2545778427"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545778427\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2545778427?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-24 10:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545778427","market":"nz","top_or_hot":-1,"title":"TransThera Gets US FDA Fast Track Designation for Prostate Cancer Drug; Shares Up 3%","media":"MT Newswires Live","content":"<html><body><p> TransThera Sciences (HKG:2617) said the US Food and Drug Administration has granted fast-track designation for tinengotinib to treat metastatic castration-resistant prostate cancer (mCRPC), according to a Tuesday Hong Kong bourse filing.</p><p>In a phase 1/2 study, the drug showed a 46% objective response rate and 85% disease control rate among 13 mCRPC patients with measurable disease, the filing said.</p><p>TransThera said the latest designation reflects consistent clinical execution and supports further development of the drug for advanced prostate cancer.</p><p>Shares of the clinical-stage biopharmaceutical firm rose about 3% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TransThera Gets US FDA Fast Track Designation for Prostate Cancer Drug; Shares Up 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTransThera Gets US FDA Fast Track Designation for Prostate Cancer Drug; Shares Up 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-06-24 10:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> TransThera Sciences (HKG:2617) said the US Food and Drug Administration has granted fast-track designation for tinengotinib to treat metastatic castration-resistant prostate cancer (mCRPC), according to a Tuesday Hong Kong bourse filing.</p><p>In a phase 1/2 study, the drug showed a 46% objective response rate and 85% disease control rate among 13 mCRPC patients with measurable disease, the filing said.</p><p>TransThera said the latest designation reflects consistent clinical execution and supports further development of the drug for advanced prostate cancer.</p><p>Shares of the clinical-stage biopharmaceutical firm rose about 3% in recent trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4104","symbol_name":"贸易公司与经销商","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2545778427","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545778427","pubTimestamp":1750730465,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"TransThera Sciences  said the US Food and Drug Administration has granted fast-track designation for tinengotinib to treat metastatic castration-resistant prostate cancer , according to a Tuesday Hong Kong bourse filing.In a phase 1/2 study, the drug showed a 46% objective response rate and 85% disease control rate among 13 mCRPC patients with measurable disease, the filing said.TransThera said the latest designation reflects consistent clinical execution and supports further development of the drug for advanced prostate cancer.Shares of the clinical-stage biopharmaceutical firm rose about 3% in recent trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4104":"贸易公司与经销商","IE00BYQQ9H92.USD":"BNY MELLON GLOBAL LEADERS \"A\" (USD) ACC","IE00BFXG0V08.USD":"BNY MELLON GLOBAL LEADERS \"B\" (USD) ACC","FAST":"快扣","BK4588":"碎股","BK4567":"ESG概念","IE00B5TLWC47.USD":"BNY MELLON LONG-TERM GLOBAL EQUITY \"B\" (USD) ACC","BK4585":"ETF&股票定投概念","02617":"药捷安康-B"},"translate_title":"TransThera获得美国FDA前列腺癌药物快速通道指定；股价上涨3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FAST":1,"02617":0.9},"content_text":"TransThera Sciences (HKG:2617) said the US Food and Drug Administration has granted fast-track designation for tinengotinib to treat metastatic castration-resistant prostate cancer (mCRPC), according to a Tuesday Hong Kong bourse filing.In a phase 1/2 study, the drug showed a 46% objective response rate and 85% disease control rate among 13 mCRPC patients with measurable disease, the filing said.TransThera said the latest designation reflects consistent clinical execution and supports further development of the drug for advanced prostate cancer.Shares of the clinical-stage biopharmaceutical firm rose about 3% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}